"Men"

Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.

Almost everyone hopes to have a young and healthy heart. However, 62% of people over 40 years old have cardiovascular disease or risk factors to varying degrees, and 80% of them have not yet fully understood how to maintain a healthy heart. Medical research shows that among all internal organs, the heart is most likely to suffer from "obesity", especially in patients with hypertension, which can also lead to gradual thickening of the heart muscle.

Prior to the granting of marketing authorisation by the MHRA, Biyze® had been approved by the European Commission for a number of indications and is currently the only drug approved for the treatment of MZL in Great Britain.

The development of an effective anti-aging drug and functional food to slow down ASCs' aging is crucial

New research by japanese scientists has found that

Most of the time, uterine cold is caused by too much cold energy in the body.

Anemia is a very common problem among women. Anemia makes people less resistant and depressed, and serious anemia can also endanger the health of the body, so when the situation of anemia occurs, it should be promptly adjusted. The actual fact is that you will be able to get a lot more than just a few of the most popular and popular items.

Osteoporosis is the cause of menopausal fractures! Do these 5 things to avoid osteoporosis

Cervical cancer is one of the most common gynecological malignancies. Its incidence rate is second only to endometrial cancer worldwide, and it ranks first in developing countries and regions. According to statistics, there are 450000 new cases of cervical cancer worldwide every year. The occurrence and development of cervical cancer usually go through a relatively long process, so it is possible to prevent this disease.

Data from a study recently published by the Royal Marsden Cancer Centre showed promising data for the combination of Avutometinib + Defactinib in the treatment of ovarian cancer, resulting in significant tumour shrinkage in 28% of patients and disease control in 93% of patients.